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From crystal structure of 
α-conotoxin GIC in complex 
with Ac-AChBP to molecular 
determinants of its high selectivity 
for α3β2 nAChR
Bo Lin1,*, Manyu Xu2,*, Xiaopeng Zhu1, Yong Wu1, Xi Liu2, Dongting Zhangsun1, Yuanyan Hu1, 
Shi-Hua Xiang4, Igor E. Kasheverov3, Victor I. Tsetlin3, Xinquan Wang2 & Sulan Luo1
Acetylcholine binding proteins (AChBPs) are unique spatial homologs of the ligand-binding domains 
of nicotinic acetylcholine receptors (nAChRs), and they reproduce some pharmacological properties of 
nAChRs. X-ray crystal structures of AСhBP in complex with α-conotoxins provide important insights 
into the interactions of α-conotoxins with distinct nAChR subtypes. Although considerable efforts have 
been made to understand why α-conotoxin GIC is strongly selective for α3β2 nAChR, this question 
has not yet been solved. Here we present the structure of α-conotoxin GIC in complex with Aplysia 
californica AChBP (Ac-AChBP) at a resolution of 2.1 Å. Based on this co-crystal structure complemented 
with molecular docking data, we suggest the key residues of GIC in determining its high affinity and 
selectivity for human α3β2 vs α3β4 nAChRs. These suggestions were checked by radioligand and 
electrophysiology experiments, which confirmed the functional role of detected contacts for GIC 
interactions with Ac-AChBP and α3β2 nAChR subtypes. While GIC elements responsible for its high 
affinity binding with Ac-AChBP and α3β2 nAChR were identified, our study also showed the limitations 
of computer modelling in extending the data from the X-ray structures of the AChBP complexes to all 
nAChR subtypes.
The discovery and crystallization of the acetylcholine-binding protein (AChBP) from a fresh-water mollusc 
Lymnaea stagnalis1,2 was a great step in understanding the structure and function of both nicotinic acetylcho-
line receptors (nAChR) and other ligand-gated ion channels belonging to the family of Cys-loop receptors. The 
first X-ray structure2, based on the disposition of the bound buffer molecule, provided the first ideas about the 
localization of the binding sites at the interface between the AChBP subunits and also between those of true 
nAChRs. It was confirmed by the subsequent X-ray structure of the AChBP complex with nicotine3, a classi-
cal agonist for most of the nAChRs subtypes. Interestingly, this structure revealed that nicotine attachment is 
accompanied by considerable movement of the AChBP loop C from the periphery to the central axis, and finally, 
nicotine appears to be embraced by this loop. In contrast, one year later, the X-ray structures for AChBP com-
plexes with antagonists such as α -cobratoxin4 or α -conotoxin PnIA (A10L, D14K)5 demonstrated that the loop 
C is shifted to the periphery by more than 10 Å. In fact, the first X-ray structures for AChBP itself and its com-
plexes with nicotine and α -cobratoxin have been established for Lymnaea stagnalis protein (Ls-AChBP), while 
the majority of the presently known AChBP complexes were solved with AChBP from the sea-water mollusc 
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Aplysia californica (Ac-AChBP) (see recent reviews6–10). These two proteins have remarkable differences in their 
affinity both to α -neurotoxins and different α -conotoxins and this is one of the factors that makes a step from 
the high-resolution X-ray structure of the AChBP complexes to the expected structures of the distinct nAChRs 
binding the same ligands more difficult. Other complications are due to the limitations of computer modelling 
methods at the stage of going from the coordinates of the AChBP complexes to the precise organization of the 
analysed particular nAChR subtype.
Our work focused on the Ac-AChBP interaction with α-conotoxins. The advantage of α-conotoxins 
is that, among other antagonists, they are the most selective tools that allow distinguishing distinct subtypes 
of nAChRs6–10. In spite of the availability of the X-ray structures of Ac-AChBPs complexes with different 
α -conotoxins5,11–13, further work is required to understand the specificity of interactions of α -conotoxins with 
distinct nAChR subtypes with complete details. Here we analysed the α -conotoxin GIC bound to the neuronal 
α 3β 2 nAChR. These receptors are present in the human brain, are involved in functions such as cognition and, 
among other neuronal nAChRs, are considered to be promising drug targets (see reviews14–16). α -Conotoxin GIC 
from Conus geographus venom is an extremely interesting peptide that potently and selectively blocks neuronal 
α 3β 2 nAChRs at very low concentrations (IC50 1.1 nM). This high selectivity for the human neuronal α 3β 2 recep-
tor makes it one of the most attractive cholinergic ligands found in recent years. Although many efforts have been 
made to understand the high selectivity of GIC for the human α 3β 2 nAChR17–19, the answer is still not clear. In 
this report, we present the co-crystal structure at a resolution of 2.1 Å of the α -conotoxin GIC in complex with 
Ac-AChBP as a further step to shed light on the selectivity mechanisms in nAChRs research.
Results
Overall structure of the complex. The Ac-AChBP expressed in insect cells was purified and co- 
crystallized with synthesized α -conotoxin GIC using the vapour diffusion sitting drop method. The crystals of 
the protein-peptide complex belong to the P212121 space group with cell dimensions of a = 78.6 Å, b = 84.9 Å, and 
c = 208.6 Å (Supplementary Table 1). The crystal structure was determined by molecular replacement and refined 
to a resolution of 2.1 Å (Supplementary Table 1).
In the complex, the Ac-AChBP exists as a windmill-like pentamer bound with five α -conotoxin GIC peptides 
(Fig. 1A). Each ligand binding site in the Ac-AChBP is located between two adjacent protomers (Fig. 1B), and the 
five binding sites are structurally very similar due to the five-fold symmetry of the Ac-AChBP pentamer (Fig. 1A). 
In the complex, the bound α -conotoxins share a common orientation, with the central helix protruding into the 
ligand binding site of Ac-AChBP and the N and C termini of the bound α -conotoxin at the bottom and top parts 
of the ligand binding site, respectively (Fig. 1C,D).
The pentameric Ac-AChBP/GIC complex is similar to previously reported complexes with other 
α -conotoxins. Upon structural superimposition, the Ac-AChBP/GIC complex structure had a RMSD of 0.71 Å 
for all paired Cα atoms compared with the Ac-AChBP/PnIA (A10L, D14K) complex (PDB code 2BR8)5, 0.54 Å 
with the Ac-AChBP/ImI complex (PDB code 2C9T and 2BYP)11,12, 0.58 Å with the Ac-AChBP/TxIA (A10L) 
complex (PDB code 2UZ6)13 and 0.60 Å with the Ac-AChBP/BuIA complex (PDB code 4EZ1). All five differ-
ent α -conotoxins displayed a similar binding mode with the central helix of the peptide protruding into the 
binding site of Ac-AChBP (Fig. 2A), but the detailed interactions are different due to amino acid differences 
among the peptides (Fig. 2B). The structure of GIC alone has been previously determined by an NMR method 
(PDB code 1UL2)17. The backbone of the GIC (residues 2–16) was structurally conserved in the unbound and 
Ac-AChBP-bound states with a RMSD of 0.53 Å in this region.
Binding interface. The GIC interacts with two adjacent Ac-AChBP protomers at the interface, forming the 
principal and complementary binding sides (Fig. 1B). Most interactions on the principal side were between the 
GIC and C loop (Gln-184 ~ Tyr-193) of one of the Ac-AChBP protomers (Fig. 1B and Table 1). The chemical 
nature of interactions at this side is a mixture of hydrophobic and hydrophilic interactions. The Cys-2/Cys-8 
disulfide bridge of the GIC stacked onto the vicinal Cys-188/Cys-189 disulfide bond of the Ac-AChBP (Fig. 3A 
and Table 1). Other significant hydrophobic interactions included the contacts of Trp-145 and Tyr-193 of the 
Ac-AChBP with surrounding GIC residues including His-5, Pro-6, Ala-7, Cys-8, Asn-11 and Asn-12 (Table 1). 
Hydrogen-bonding interactions occurred between Asn-11 and Asn-12 of the GIC with Tyr-193 and Glu-191 
of the Ac-AChBP, respectively (Fig. 3A). The complementary binding side was between the GIC and β -sheet of 
another Ac-AChBP protomer in the interface (Table 1). On this side, a notable interacting residue in the GIC 
was Gln-13, whose side chain resided in a pocket consisting of residues contacts with Arg-57, Val-106, Thr-108, 
Ser-112 and Met-114 of Ac-AChBP (Fig. 3B). Gln-13 also formed a hydrogen bond with Ser-112 of Ac-AChBP 
(Fig. 3B). On this side, additional hydrogen-bonding interactions included GIC Ser-4 to Ac-AChBP Ser-164 and 
Ser-165 and GIC Asn-11 to Ac-AChBP Arg-77 (Fig. 3B).
Molecular docking and modelling of GIC complexes with the α3β2 nAChR subtype. GIC 
potently blocks the α 3β 2 subtype of human nAChR, showing the highest known selectivity (100,000-fold selec-
tivity for the α 3β 2 subtype vs the muscle receptor of nAChR) for neuronal versus muscle subtypes of any nic-
otinic ligand characterized to date18. Using the co-crystal structure of Ac-AChBP/GIC as a template, we first 
modelled the structures of the α 3 and β 2 subunits and then generated a α 3β 2/GIC complex model. The inter-
acting residues of the GIC and the α 3β 2 nAChR are listed in Table 1. The GIC-contacting residues in the α 3β 2 
nAChR and Ac-AChBP are very similar in both position and chemical property of the side chain (Table 1). One 
notable change is the substitution of Ser-148 in the Ac-AChBP with Asp-152 in the α 3β 2 nAChR. In the α 3β 2/
GIC model, the α 3 subunit Asp-152 has more extensive interactions with GIC Asn-11 than the Ac-AChBP Ser-
148 does in the Ac-AChBP/GIC crystal structure. Another notable change is the substitution of Arg-57 in the 
Ac-AChBP with Glu-61 in the α 3β 2 nAChR. The residue change would not significantly affect the GIC binding 
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because Arg-57 in the Ac-AChBP and Glu-61 in the α 3β 2 nAChR are just involved in the formation of the pocket 
for GIC Gln-13, and both residues have no specific interactions with GIC in the Ac-AChBP/GIC crystal structure 
and α 3β 2/GIC model.
According to the structural and docking data, GIC His-5, Ala-7, Asn-11, Asn-12 and Gln-13 are residues 
that form the largest number of interactions with the Ac-AChBP or α 3β 2 nAChR (Table 1). Therefore, we chose 
these five sites and synthesized six GIC analogues (i.e., His5Ala, Ala7Gly, Ala7Leu, Asn11Ala, Asn12Ala and 
Gln13Ala) with single-site mutations in each analogue (Table 2). The wild-type GIC and these six analogues were 
synthesized by solid-phase peptide synthesis. The characterization of the synthetic GIC mutants by reverse-phase 
high performance liquid chromatography (HPLC) and mass spectrometry are shown in Supplementary Figure 1. 
All α -conotoxin GIC and its mutant peptides have CD spectra consistent with the CysI-III, CysII-IV disulphide 
isomer containing a helical character (See Supplementary Figure 2). We first studied the binding of these GIC 
Figure 1. The X-ray crystal structure of Ac-AChBP in complex with α-conotoxin GIC. (A) The top view of 
the pentameric structure with five Ac-AChBP protomers, each in different colours and five α -conotoxin GIC 
molecules in magenta. (B) The side view of two adjacent protomers of the pentamer with a bound α -conotoxin 
GIC molecule (in magenta). (C) The side view of the surface model of two adjacent protomers with a bound 
α -conotoxin GIC molecule (in magenta) inside the binding pocket. (D) Fo-Fc electron density omit map 
contoured at 3.0 σ surrounding the GIC.
www.nature.com/scientificreports/
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analogues (in comparison with wild-type GIC) towards the Ac-AChBP by measuring their abilities to compete 
with [125I]-labelled α-bungarotoxin in a radioligand assay. In the dose response experiment, the wild-type GIC 
exhibited a complete inhibition of radioligand binding with IC50 = 29 ± 2 nM (Fig. 4A). Among the studied GIC 
mutants, only the Gln13Ala substitution essentially did not change the affinity for Ac-AChBP (Fig. 4B). The sub-
stitutions of Ala-7, Asn-11 and Asn-12 in GIC resulted in approximately one order drop in the binding affinity for 
Ac-AChBP (Fig. 4B). The most significant change was observed for the His5Ala mutation with an almost 100-fold 
increase in the IC50 value (Fig. 4B). We then tested the inhibition of the α 3β 2 nAChR by these GIC mutants in an 
electrophysiology experiment. All six GIC analogues except Gln13Ala showed a very significant decrease in the 
inhibition of the α 3β 2 nAChR compared with wild-type GIC (Table 2). The GIC analogues bearing the Ala7Leu 
Figure 2. Comparison of different α-conotoxins bound by Ac-AChBP. (A) Backbone orientations observed 
in co-crystal structures of Ac-AChBP with five α -conotoxins. The backbone of GIC is shown in magenta, PnIA 
(A10L, D14K) in orange, ImI in light blue, TxIA (A10L) in red and BuIA in yellow. (B) Multiple sequence 
alignment of α -conotoxins GIC, PnIA (A10L, D14K), TxIA (A10L), ImI and BuIA. Disulfide bridges between 
Cys2-Cys8 and Cys3-Cys16 are shown in red.
GIC/Ac-AChBP crystal structure GIC/α3β2-nAChR model
Principal side
GIC Ac-AChBP GIC α 3β 2
His-5 Tyr-91 His-5 Tyr-93
Pro-6, Ala-7 Trp-145 Pro-6, Ala-7 Trp-149
Ala-7 Val-146 Ala-7 Ser-150
Asn-11 Ser-148 Ala-7, Asn-11 Asp-152
Gly-1, Cys-2, His-5, Cys-8 Tyr-186 Gly-1, Cys-2, His-5, Cys-8 Tyr-190
Cys-2 Cys-188 Asn-12, Ile-15 Cys-192
Asn-12 Cys-189 Asn-12 Cys-193
Asn-11, Asn-12 Glu-191 Asn-11, Asn-12 Glu-195
His-5, Ala-7, Cys-8, Asn-11, Asn-12 Tyr-193 His-5, Cys-8, Asn12 Tyr-197
Complementary side
Ser-4 Thr-34 Ser-4 Ser-38
Ser-4, Pro-6 Tyr-53 Ser-4, His-5, Pro-6 Trp-57
Ala-9, Cys-16 Gln-55
Gln-13 Arg-57 Gln-13, Cys-16 Glu-61
Asn-11 Arg-77 Asn-11 Arg-81
Gly-10, Gln-13 Val-106 Gly-10, Gln-13 Val-111
Gln-13 Thr-108
Gln-13 Ser-112 Gln-13 Ser-117
Ala-9, Gly-10, Gln-13 Met-114 Ala-9, Gly-10, Gln-13 Phe-119
Pro-6, Ala-9 IIe-116 Leu-121
Cys-16 Asp-157
Ser-4 Asp-162, Ser-164, Ser-165 Ser-4 Asp-171
Table 1. Amino acid contacts with a distance cutoff 4.0 Å between α-conotoxin GIC and Ac-AChBP from 
the X-ray structure or α3β2 nAChR from modelling.
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or His5Ala mutation exhibited a more than 10,000-fold decrease in the inhibition (Table 2). These data further 
support our α 3β 2/GIC model built on the Ac-AChBP/GIC crystal structure.
Potential structural basis for the high selectivity of GIC towards the α3β2 subtype. GIC exhib-
its a high affinity (~1 nM) to the α 3β 2 nAChR, but a much lower (~700 nM) affinity towards the α 3β 4 nAChR 
(Table 2). Sequence alignment of Ac-AChBP, AChBP from Lymnaea stagnalis (Ls-AChBP), as well as of human 
β 2 and β 4 nAChR subunits, are shown in Supplementary Fig. 3. The regions of nAChR subunits forming the 
binding sites are shown in Fig. 5A (summary from Supplementary Figure 3). With the structure of Ac-AChBP/
GIC as a template, we also docked the GIC onto human α 3β 4 nAChR models. The comparison of the α 3β 2/
GIC model, α 3β 4/GIC model and Ac-AChBP/GIC crystal structure allowed us to pinpoint the key amino acid 
residues on the complementary side, which appear to be responsible for selectivity of GIC for α 3β 2 vs α 3β 4. In 
the GIC/α 3β 2 model, the Gln-13 of GIC resides in a pocket surrounded by Glu-61, Val-111, Ser-113, Ser-117 and 
Phe-119 residues of the β 2 subunit (Fig. 5B), which is very similar to the respective pocket formed by Arg-57, 
Val-106, Thr-108, Ser-112 and Met-114 residues on the complementary side of Ac-AChBP (Fig. 3B). No steric 
clashes were found between Gln-13 of GIC and the α 3β 2 receptor in the model, thus providing an explanation 
for a high affinity to both Ac-AChBP and the α 3β 2 receptor. Residues forming the pocket in the β 4 subunit were 
changed to Glu-62, Ile-113, Arg-115, Ser-119 and Leu-121, which, except for Arg-115, were the same or similar to 
the respective residues in the β 2 subunit (Fig. 5A). This position in the Ac-AChBP and Ls-AChBP are threonine 
and valine, respectively (Fig. 5A). Arg-115, which has a longer side chain compared to serine, threonine and 
valine, could bring steric hindrance in this pocket to accommodate Gln-13 of GIC and could even directly clash 
Figure 3. Binding interface between GIC and Ac-AChBP. (A) The disulfide bridge packing and hydrogen-
bonding interactions (represented by black dashed line) on the principal side. Residues Asn-11 and Asn-12 of 
the GIC form hydrogen bonds with Tyr-193 and Glu-191 of the Ac-AChBP, respectively. Disulfide bond C2-C8 
in the GIC closely packed together with C-188-C189 in the Ac-AChBP. (B) On the complementary side, the 
Gln-13 residue of GIC was located in a pocket surrounded by residues Arg-57, Val-106, Thr-108, Ser-112 and 
Met-114 of Ac-AChBP. Asn-11 of the GIC forms a hydrogen bond with Arg-77 of the Ac-AChBP. Ser-4 of the 
GIC also makes two hydrogen bonds with Ser-164 and Ser-165 of the Ac-AChBP.
Peptide Sequence Subtype IC50 (nM) Hill Slope Subtype IC50 (nM)
GIC GCCSHPACAGNNQHIC* hα 3β 2 1.13(1.10–1.16) 0.764(0.559–0.969) hα 3β 4 750(710–790)
GIC(Q13A) GCCSHPACAGNNAHIC* hα 3β 2 8.41(7.027–10.01) 1.078(0.823–1.332) hα 3β 4 660(630–690)
GIC(N12A) GCCSHPACAGNAQHIC* hα 3β 2 1980(840–4660) 0.35(0.238–0.463) hα 3β 4 > 10000
GIC(N11A) GCCSHPACAGANQHIC* hα 3β 2 1600(545–4720) 0.491(0.222–0.760) hα 3β 4 > 10000
GIC(A7L) GCCSHPLCAGNNQHIC* hα 3β 2 > 10000 — hα 3β 4 > 10000
GIC(A7G) GCCSHPGCAGNNQHIC* hα 3β 2 4210(1566–11330) 0.371(0.222–0.521) hα 3β 4 > 10000
GIC(H5A) GCCSAPACAGNNQHIC* hα 3β 2 > 10000 — hα 3β 4 > 10000
Table 2. Amino acid sequences and blocking activities (in IC50s, nM) of α-conotoxin GIC and its analogues 
on expressed nAChR subtypes. *C-terminal carboxamide.
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Figure 4. The binding affinity of α-conotoxin GIC and its mutants to Ac-AChBP measured by a 
competitive radioligand assay. (A) The inhibition curve for α -conotoxin GIC wild-type is shown. Each point is 
a mean ± s.e.m value of two measurements for each concentration of one experiment. The curve was calculated 
from the means ± s.e.m. using the ORIGIN 7.5 program. The calculated IC50 value is 29 ± 2 nM. (B) The bar 
diagram showing the differences in IC50 values for GIC mutants in comparison with wild-type peptides.
Figure 5. Structure basis for the selectivity of GIC with α3β2 vs α3β4 nAChR. (A) Primary sequence 
comparison of Ac-AChBP, Ls-AChBP, human β 2 and human β 4 residues forming the pocket on the 
complementary binding side to accommodate Gln-13 of the GIC. (B) The pocket in human β 2 is able to 
accommodate Gln-13 of the GIC without steric clashes in the α 3β 2/GIC model. (C) Arg-115 in the pocket of 
human β 4 could bring steric hindrance and even steric clashes with Gln-13 of the GIC and then disfavour the 
binding of α 3β 4 compared with α 3β 2 nAChR.
www.nature.com/scientificreports/
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with it (Fig. 5C). The presence of arginine at this position would not favour the binding of the GIC with the α 3β 4 
nAChR compared with the α 3β 2 nAChR, which is also represented by the decreased inhibition ability of GIC 
against the α 3β 4 receptor (Table 2).
Discussion
Before this study, co-crystal structures of four different α -conotoxins in complexes with Ac-AChBP have been 
reported, namely for the PnIA variant (PDB code 2BR8)5, TxIA variant (PDB code 2UZ6)13, ImI (PDB code 2C9T 
and 2BYP)12 and BuIA (PDB code 4EZ1). All Ac-AChBP/α -conotoxin co-crystal structures are similar, but the 
residues interacting at the binding sites are different (Supplementary Table 2). As a result, different α -conotoxins 
exhibit a wide range in selectivity towards distinct nAChR subtypes, reflected in different pharmacological prop-
erties (Supplementary Table 3). The Ac-AChBP/TxIA (A10L) co-crystal structure showed that the Arg-5 of TxIA 
(A10L) forms a hydrogen bond with Tyr-186 and a salt bridge with Asp-195 residues of loop C, which account 
for the high binding affinity of this conotoxin variant to Ac-AChBP. A docking study of TxIA (A10L) onto α 3β 2 
nAChR suggested that Arg-5 could have a salt bridge with Asp-197 and a hydrogen bond with Tyr-188 of the α 3 
subunit (corresponding to Asp-195 and Tyr-186 in Ac-AChBP)13. The Ac-AChBP/ImI co-crystal structure indi-
cated that α -conotoxin Trp-10 residue could play a key role in binding to α 3β 2 nAChR. Substitution of Thr-57 
in the β 2 subunit by Lys-59 in the β 4 subunit would result in steric clashes with the Trp-10 residue of ImI, which 
explains the decreased affinity for the α 3β 4 subtype7,12. α -Conotoxin GIC is one more α -conotoxin of strong 
selectivity for α 3β 2 nAChR. Compared with TxIA(A10L) and ImI, GIC does not contain the same respective 
Arg-5 or Trp-10 residues responsible for α 3β 2 binding and selectivity. Instead, it has His-5 and Gln-13 residues 
in these two positions.
Through the co-crystal structure of Ac-AChBP/GIC and the GIC docking to different nAChR subtypes, we 
came to the conclusion that His-5 and Gln-13 of GIC are important residues for its α 3β 2 nAChR binding and 
selectivity, respectively. These conclusions were further supported by the studies of GIC analogues in Ac-AChBP 
binding and α 3β 2 nAChR inhibition. The radioligand binding and electrophysiology experiments were different 
in sensitivity, but the results from both experiments revealed a common tendency: the His5Ala mutant showed 
the largest drop in ability for Ac-AChBP binding and for the α 3β 2 nAChR functional blocking, and the Gln13Ala 
substitution had the least influence on GIC activity in both experiments (Fig. 4B and Table 2). In accordance with 
the co-crystal structure, the His5Ala mutation led to a dramatic (by almost 2 orders of magnitude) decrease in 
affinity for Ac-AChBP. As shown in Table 1, the His-5 interacted extensively with Tyr-91, Tyr-186 and Tyr-193 
of the Ac-AChBP and its mutation to Ala would lead to less interaction and decreased binding. In the α 3β 2/GIC 
model, His-5 of GIC also interacted with three tyrosines (i.e., Tyr-93, Tyr-190 and Tyr-197) of the α 3 subunit. 
Therefore, its mutation to alanine would decrease its inhibitory effect by reducing the interactions with surround-
ing tyrosine residues in the α 3 subunit. Similar to the His-5 position, substitutions of amino acid residues in Ala-
7, Asn-11 and Asn-12 positions involved in the interactions on the principal side also had a significant impact 
on the activity of GIC in both assays (Fig. 4B and Table 2). Asn-11 and Asn-12 participate in the interaction with 
Ac-AChBP by forming hydrogen bonds with Glu-191 and Tyr-193 (Fig. 3A), and these two residues in Ac-AChBP 
were conserved in the α 3 subunit. Ala-7 in GIC was different from the proline in PnIA, TxIA and BuIA and 
arginine in ImI. It formed hydrophobic interactions with Trp-145, Val-146 and Tyr-193 of Ac-AChBP. A change 
to leucine or glycine seems to break these interactions and thus reduce the activity of GIC (Fig. 4B and Table 2). 
These results, together with previous studies on other α 3β 2 nAChR selective α -conotoxins, suggested that the 
high affinity and specificity of α -conotoxin to the α 3β 2 nAChR subtype is determined basically by its interactions 
with the principal side of this receptor20.
In contrast, for Gln-13, which resides in a pocket formed by residues Arg-57, Val-106, Thr-108, Ser-112 and 
Met-114 on the complementary side of Ac-AChBP (Fig. 3B), its replacement for alanine did not significantly affect 
the activity in both assays (Fig. 4B and Table 2). Because the binding of GIC with Ac-AChBP or α 3β 2 nAChR is 
basically determined by multiple interactions on the principal side, a mutation of Gln-13, which is involved in the 
interactions on the complementary side, would not significantly affect the activity of GIC in Ac-AChBP binding 
and α 3β 2 nAChR inhibition. Previous studies have proposed that α -conotoxin residues on the complementary 
side, such as the Trp-10 in ImI, are important for the receptor selectivity of the toxin. Our docking studies with 
α 3β 2 vs α 3β 4 models also supported this suggestion. In the α 3β 2/GIC model, no steric clashes were found 
between Gln-13 of GIC and the β 2 receptor subunit, which had a similar pocket consisting of Glu-61, Val-111, 
Ser-113, Ser-117 and Phe-119 (Fig. 5B). It provided an explanation for high affinity to both Ac-AChBP and α 3β 2 
receptors by GIC. In contrast, the Arg-115 residue of the human β 4 subunit, instead of threonine in Ac-AChBP 
and serine in the human β 2 subunit (Fig. 5A), could have steric clashes with Gln-13 residues of GIC (Fig. 5C), 
which may explain the low affinity of GIC towards the α 3β 4 receptor subtype and its high selectivity of α 3β 2 vs 
α 3β 4. Our data from the co-crystal structure may also explain why Ls-AChBP shows a 10-fold decreased affinity 
for GIC in comparison with Ac-AChBP (Supplementary Table 3): the Arg-104 residue of Ls-AChBP (Val-106 
Ac-AChBP) could also have steric clashes with the Gln-13 residue of GIC on the complementary side (Fig. 5A).
The models of α -conotoxin GIC complexes with α 3β 2 and α 3β 4 nAChRs were previously generated using 
methods of molecular docking 19. These models suggested that the GIC’s higher affinity for α 3β 2 vs α 3β 4 was 
due to the residues in the α 3β 2 subtype that are more closely located to the ligand than the respective residues in 
the α 3β 4 subtype. However, why the residues in the α 3β 2 subtype are situated more closely to GIC has not been 
explained. Our model based on the AChBP co-crystal structure allowed us to conclude that the major reason for 
α 3β 4 decreased affinity for GIC is probably the steric clashes between the Arg-115 residue of the β 4 subunit and 
the peptide Gln-13 residue.
Notably, none of the substitutions led to an increase in the GIC affinity for α 3β 4 nAChR (Table 2). In general, 
our results demonstrated that more sophisticated computer methods are required to correctly transfer the data 
from the co-crystal structure of α -conotoxin or any other ligand, with a model like Ac-AChBP, to a true receptor. 
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Even for the model as such, from the two most important GIC residues (His-5 and Gln-13), in our view, we 
experimentally could confirm only the role of His-5. This residue was also shown to be essential for recognition of 
α 3β 2 nAChR. It also should be noted that GIC has a high affinity both for Ac-AChBP and α 3β 2 nAChR, and the 
importance of one or another GIC residue was demonstrated by a decrease in the affinity of the chosen mutants. 
However, in the case of α 3β 4 nAChR, the task was the opposite: it was expected that the chosen GIC substitutions 
will raise the affinity to those subtypes. In general, increasing the affinity (or activity) is always a much more 
challenging task. Apparently, the co-crystal structure of GIC with Ac-AChBP is a good starting point and only 
extensive subsequent creation of substituted α -conotoxin libraries and a broad mutagenesis of the particular 
nAChR of interest will unravel the fine mechanisms of binding and might assist the design of more potent and 
selective antagonists and agonists.
In summary, we first determined the crystal structure of GIC with Ac-AChBP. Based on this structure, we 
obtained a more accurate model of α -conotoxin GIC complexed with α 3β 2 and also presented possible expla-
nations for the high selectivity of GIC for α 3β 2. We believe that these results will help develop a better under-
standing of the α -conotoxin selectivity for distinct nAChR subtypes and may facilitate the design of α -conotoxin 
analogues for therapeutic purposes.
Materials and Methods
Chemical synthesis of GIC and its mutants. The linear peptides were assembled by solid-phase meth-
odology on an ABI 433A peptide synthesizer (Applied Biosystems Inc., Foster City, CA, USA) using FastMoc 
[N-(9-fluorenyl)methoxycarbonyl] chemistry and standard side-chain protection, except for cysteine residues. 
A two-step oxidation protocol was used to fold the peptide selectively, as described previously20. Briefly, to form 
first disulfide bridge between Cys2 and Cys8, the peptides were added slowly to an equal volume of 20 mM potas-
sium ferricyanide K3[Fe(CN)6] and 0.1 M Tris base, with the pH adjusted to 7.5 with acetic acid. The solution 
was mixed to react for 45 min, and the monocyclic peptide was purified by reverse-phase HPLC. Simultaneous 
removal of the S-acetamidomethyl groups and closure of the disulfide bridge between Cys3 and Cys16 was car-
ried out by iodine oxidation, the bicyclic peptide was purified by HPLC on a reversed-phase C18 Vydac column 
(Hesperia, CA, USA) using a linear gradient of 10–40% B90 in 30 min. Solvent B was 90% ACN, 0.092% TFA, 
and H2O; Solvent A was 0.1% TFA in H2O. Analytical reversed phase-HPLC (Waters ACQUITY UPLC H-Class) 
and ESI -IT-TOF (Shimadzu, Kyoto, Japan) mass spectrometry confirmed the purity and molecular mass of the 
synthesized peptides. The purity and correctness of the structure of synthesized products were checked by HPLC 
re-chromatography and ESI mass-spectrometry (Fig. 1 Supplementary).
Protein expression and purification. The Ac-AChBP was expressed using the Bac-to-Bac baculovi-
rus expression system (Invitrogen). Spodoptera frugiperda Sf9 insect cells were maintained in Insect-Xpress 
protein-free medium (Lonza) without serum. Full length Ac-AChBP with a C-terminal 6× His tag was cloned 
into the pFastBac-Dual vector (Invitrogen). The construct was transformed into bacterial DH10Bac compe-
tent cells, and the extracted bacmid was transfected into Sf9 cells using Cellfectin II Reagent (Invitrogen). The 
low-titre viruses (P0) were harvested after incubation of the transfected cells at 26 °C for 7 ~ 9 d and then ampli-
fied to generate a high-titre virus stock. The amplified high-titre viruses (P1) were used to infect 1 L of Sf9 cells at 
a density of 2 × 106 cells/ml. The supernatant of the cell culture containing soluble Ac-AChBP was harvested 48 h 
after infection and concentrated and buffer-exchanged to HBS (10 mM Hepes, pH 7.2, 150 mM NaCl). Ac-AChBP 
was captured by Nickel-charged resin (GE Healthcare) and eluted with 500 mM imidazole in HBS buffer 
(pH 7.2). Further purification was performed by gel-filtration chromatography using the Superdex 200 column 
(GE Healthcare).
Crystallization and data collection. Purified Ac-AChBP and synthesized α -conotoxin GIC were mixed 
at a molar ratio 1:1.5 at 4 °C for 2 h and then loaded to a Superdex 200 column. The complex was collected and 
concentrated to ~20 mg/ml in HBS buffer for crystallization. Crystals were successfully grown at 18 °C using the 
sitting drop vapour diffusion method by mixing equal volumes of protein and reservoir solution containing 1.5 M 
lithium sulfate monohydrate, 0.1 M Tris, PH 8.5. Crystals were cryocooled in liquid nitrogen with cryoprotectant 
(reservoir solution plus 20% (v/v) glycol) before data collection. Diffraction data were collected at the BL17U 
beam line of the Shanghai Synchrotron Research Facility (SSRF). Diffraction data were indexed, integrated and 
scaled with the program HKL200021.
Structural determination and refinement. The structure was determined by the molecular replacement 
method with PHASER22 in CCP4 suite23. The search model was Ac-AChBP–PnIA (D14K, A10L) (PDB code 
2BR8). Iterative structural refinement was performed with the program PHENIX24 and the structure validation 
was performed by the program PROCHECK25. All structural figures were made with PyMol26.
Molecular modelling, docking and simulations. All the modelling, docking and simulations were 
performed in Discovery Studio Client 4.0 (Accelrys, San Diego, CA). The molecular models of extracellular 
ligand-binding domains of the human nAChRs such as (α 3)2(β 4)3, (α 3)2(β 2)3 were generated based on the tem-
plate of Ac-AChBP structure using the homology modelling program Modeler version 9.0. The GIC docking was 
based on the reference model of the Ac-AChBP/GIC complex. The models were refined with a side-chain refine-
ment and energy minimization process. The CHARMm forcefield was used for all simulations. All modelling and 
docking structures were verified by the program Profiles-3D in the Discovery Studio platform27, as well as by the 
MolProbity server28,29.
Competitive radioligand assay. For competitive radioligand assays we used 6× His tagged Ac-AChBP 
and Ls-AChBP, kindly provided by Prof. A.B. Smit (Free University of Amsterdam, the Netherlands), which 
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were expressed and purified mainly as described above for Ac-AChBP. The competition experiments with 
[125I]-labelled α -bungarotoxin were carried out mainly as described in ref. 30. Shortly, α -conotoxin GIC or its 
mutants (in a concentration range of 0.03–100 μM) were pre-incubated 3 h at room temperature with the Ls- or 
Ac-AChBPs (the final protein concentration of 2.4 nM or 140 nM, respectively) in 50 μL of binding buffer (20 mM 
Tris-HCl buffer, 1 mg/mL of bovine serum albumin, pH 7.9). Next, [125I]- labelled α -bungarotoxin was added to 
final concentration 0.2 nM and the mixtures were additionally incubated for 5 min. Binding was stopped by rapid 
filtration on double DE-81 filters (Whatman) pre-soaked in binding buffer, unbound radioactivity being removed 
from the filters by washout (3 × 3 mL) with the binding buffer. Non-specific binding was determined in all cases 
using 3 h pre-incubation with 10 μM α -cobratoxin from Naja kaouthia venom.
The binding results were analysed using ORIGIN 7.5 (OriginLab Corporation, Northampton, MA, USA) 
fitting to a one-site dose-response curve by the equation: % response = 100/{1 + ([toxin]/IC50) n, where IC50 is the 
concentration at which 50% of the binding sites are inhibited and n is the Hill coefficient30 .
Electrophysiology measurements and data analysis. The cRNAs of nAChR subunits (kindly pro-
vided by S. Heinemann, Salk Institute, San Diego, CA, USA) were obtained by in vitro transcription using the 
mMessage mMachine SP6 kit (Ambion, Austin, TX, USA). The MEGAclearTM kit (Ambion) was used to purify 
the cRNAs. Oocytes of Xenopus laevis were prepared and injected with capped RNA (cRNA) to express human 
α 3β 2, and human α 3β 4 nAChRs. Oocytes were injected within one day of harvesting and recordings were made 
1–4 days post-injection, as described previously18. Briefly, oocytes were transferred to the recording chamber 
(~50 μL in volume) and gravity-perfused at 2 mL/min with ND-96 buffer containing 0.1 mg/mL bovine serum 
albumin (BSA). ACh-gated currents were obtained with a two-electrode voltage-clamp amplifier (Axoclamp 
900A, Molecular Devices Corp., Sunnyvale, CA, USA). Oocytes were voltage clamped at − 70 mV at room tem-
perature. The continuous gravity perfused with standard ND-96 solution and stimulated with 2-s pulses of ACh 
once every minute. A total of 5 μL of different concentration toxins were placed in the chamber for 5 min, and 
then the perfusion system was applied during which 2-s pulses of 100 μM ACh were applied every minute until a 
constant level of blockage was achieved. The final results were acquired for at least 4 oocytes. The dose-response 
data were fitted to the equation: % Response = 100/{1 + ([toxin]/IC50)nH}, Each data point of the dose-response 
curve represents the average ± S.E. of 4 to 6 oocytes, where nH is the Hill coefficient, by nonlinear regression anal-
ysis using GraphPad Prism (GraphPad Software, San Diego, CA, USA)18.
PDB deposition. The coordinates and diffraction data have been deposited into the Protein Data Bank with 
accession code 5CO5.
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